濮阳东方医院妇科做人流安全(濮阳东方妇科口碑评价很好) (今日更新中)

The Trump administration on Thursday imposed penalties on 17 individuals over their alleged roles in the killing of dissident journalist Jamal Khashoggi.The fresh sanctions from the Treasury Department come hours after Saudi prosecutors said they would seek the death penalty for five people charged in the death of Khashoggi, who was a contributor to The Washington Post."The Saudi officials we are sanctioning were involved in the abhorrent killing of Jamal Khashoggi," said Treasury Secretary Steven Mnuchin in a statement. "These individuals who targeted and brutally killed a journalist who resided and worked in the United States must face consequences for their actions."The secretary said the US government would work "diligently" to obtain all the facts on the death of Khashoggi and hold "accountable" any individual found responsible."The Government of Saudi Arabia must take appropriate steps to end any targeting of political dissidents or journalists," he said.Mnuchin had previously told reporters it would be "premature" to discuss whether the US would impose sanctions on the Saudi government.Earlier on Thursday, the Saudi Public Prosecutor's office said a total of 11 people were charged, adding that the five people facing capital punishment were directly involved in "ordering and executing the crime."The prosecution also shared details of the journalist's murder, saying Khashoggi was killed on October 2 following "a fight and a quarrel" at the Saudi consulate in Istanbul. Prosecutors say Khashoggi was tied up and injected with an overdose of a sedative that killed him, then his body was chopped up and given to a local collaborator. 1668

The U.S. will pay more than billion for 100 million doses of a potential Covid-19 vaccine manufactured by Johnson & Johnson.The deal is one of several large agreements between the government and pharmaceutical companies as part of Operation Warp Speed, aimed at creating, testing, manufacturing and distributing a Covid-19 vaccine quickly.The Trump administration’s deal with Johnson & Johnson, announced Wednesday, allows for the purchase of an additional 200 million doses.Johnson & Johnson’s vaccine, developed by subsidiary Janssen Pharmaceutical Companies, has shown positive preclinical results. Testing of their vaccine is currently underway with human trials in the United States and Belgium.The Johnson & Johnson vaccine testing is reportedly behind some of the more advanced-stage potential vaccines, like those from Moderna, Pfizer and AstraZeneca, which have begun phase three human trials.“We greatly appreciate the U.S. government’s confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the U.S. and worldwide to deliver a SARS-CoV-2 vaccine for emergency use,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson in a statement.The company says they are committed to global access to the vaccine following approvals, and has a goal of supplying 1 billion doses globally through the end of 2021. 1493

The stars of country music, along with an assortment of stars from Hollywood, have converged on Nashville on Wednesday for the annual CMA Awards.  159

The weekend didn't make things any easier for students of Marjory Stoneman Douglas High School: Parents had to lay teen children to rest; the family who had taken in shooter Nikolas Cruz said they didn't know they were living with a "monster;" and a tweet from President Donald Trump seemed to infuriate an already-angry student body.The students promised action in the wake of the massacre that left 17 of their classmates and teachers dead. They're headed to Tallahassee, Florida, to speak to legislators about school safety and gun control this week, and they have school walkouts and a march scheduled in the coming months.Meanwhile, Anthony Borges, 15, continued his recovery. He's one of four patients who remain hospitalized after Wednesday's massacre in Parkland, Florida. He was shot five times, according to the Broward County Sheriff's Office.  868

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

来源：资阳报